Shorts covered.

All information is on the table in terms of timing.  

Dual Epitaxy suppliers now working for POET.    

Partnerships, NRE, completed VCSEL, Denselight cash flow positive, completed protype- all these items are going to help us in 2017.   

I see very limited downsisde  and good upside from here.  PTK is oversold.  

Yes, more patience is required, but 2017 is looking very interesting.